Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | ESRRA | P11474 | 7/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157763 | 0.89 | FAAH (0.47) | DDX3XS1PR1ESRRABCHECA12 | |
| SCHEMBL14567878 | 0.86 | BCHE (0.54) | S1PR1BCHECA12CA1CA2 | |
| SCHEMBL17795645 | 0.85 | BCHE (0.56) | S1PR1BCHECA12CA1CA2 | |
| SCHEMBL13527027 | 0.82 | BCHE (0.41) | S1PR1ESRRACTSCBCHECA12 | |
| SCHEMBL21157743 | 0.80 | BCHE (0.42) | DDX3XS1PR1BCHECA12CA1 | |
| SCHEMBL21156872 | 0.80 | GLA (0.53) | DDX3X | |
| SCHEMBL21157740 | 0.80 | NOTUM (0.57) | DDX3XBCHECA12CA1CA2 | |
| SCHEMBL21156929 | 0.79 | MIF (0.50) | DDX3XBCHECA1CA2CA9 | |
| SCHEMBL21156928 | 0.78 | MIF (0.52) | DDX3XBCHECA12CA1CA2 | |
| SCHEMBL21156459 | 0.77 | NOTUM (0.52) | DDX3XBCHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | DDX3X 3177/4885S1PR1 1144/4885ESRRA 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.